Aim: Peripheral artery occlusive disease (PAOD) is associated with
associated with an ABI less than 0.9 in multivariate analysis (odds ratio, 5.688; 95% confidence interval, 1.369-23.626; P = 0.017) after adjusting for demographic, clinical, biochemical and medication data. The interaction between albumin and CRP in relation to an ABI less than 0.9 was significant in multivariate analysis (odds ratio, 1.797; 95% confidence interval, 1.258-2.568; P = 0.001). The areas under the curve for albumin, CRP and albumin + CRP for the prediction of ABI less than 0.9 were 0.311, 0.654 and 0.733, respectively.
Conclusion:
Patients undergoing haemodialysis with a lower albumin level and higher CRP level have an increased risk of PAOD. A combination of malnutrition and inflammation may be associated with PAOD in haemodialysis patients.
Peripheral artery occlusive disease (PAOD) is an important manifestation of systemic atherosclerosis, and is prevalent among patients with end-stage renal disease (ESRD). 1 The ankle-brachial index (ABI) is a non-invasive diagnostic tool, and an ABI less than 0.9 has been used to diagnose PAOD in the general population and in patients undergoing dialysis. 2, 3 Previous studies have reported that a high prevalence of patients on dialysis with an ABI less than 0.9, 4,5 and PAOD is associated with an increased risk of cardiovascular mortality, morbidity and hospitalization in dialysis patients. 6 The pathophysiological mechanisms contributing to PAOD are multi-factorial and complex. Accumulating evidence *These two authors contributed equally to this study.
suggests that both inflammation and malnutrition are common in patients on dialysis. 7, 8 In addition, inflammation and malnutrition have been reported to play key roles in the pathophysiological pathways involved in progression to atherosclerosis and PAOD, respectively. 9,10 However, few studies have investigated associations between inflammation, malnutrition and PAOD in patients on dialysis. We hypothesized that interactions between inflammation and malnutrition may be associated with PAOD. In this study, we used serum C-reactive protein (CRP) and serum albumin as markers of inflammation and malnutrition, respectively, to evaluate associations among inflammation, malnutrition and their interactions on the risk of PAOD in patients on haemodialysis.
METHODS

Study patients and design
This study was conducted at a regional hospital in Taiwan. All patients receiving haemodialysis three times a week at this hospital were enrolled. We excluded five patients who refused to undergo ABI-form device examinations, four patients with atrial fibrillation, two patients with bilateral below the knee amputations, and five patients who had been hospitalized 4 weeks prior to study enrolment. Overall, 222 patients (115 men and 107 women) were included into the final analysis. The study protocol was approved by the Institutional Review Board of Kaohsiung Medical University Hospital, and written informed consent was obtained from all patients.
Haemodialysis
All study patients underwent routine haemodialysis three times a week. Each haemodialysis session lasted for 3-4 h, with a blood flow rate of 250-300 mL/min and a dialysate flow rate of 500 mL/min.
Demographic, medical and laboratory data
Data of age, sex, smoking history (ever vs never) and comorbidities were recorded from interviews with the patients and their medical records. Body mass index was calculated as the patient's bodyweight/body height squared (kg/m 2 ).
An autoanalyzer (Roche Diagnostics GmbH, Mannheim, Germany, D-68298 Mannheim COBAS Integra 400) was used for all laboratory data measurements using fasting blood samples that were obtained within 1 month of enrolment. Levels of CRP were measured using a commercially available kit (Dade Behring Marburg GmbH, Marburg, Germany). Kt/V was evaluated monthly according to the Daugirdas procedure as a marker of dialysis adequacy. 11 In addition, the use of medications including β-blockers, calcium channel blockers, angiotensin converting enzyme inhibitors (ACEI), angiotensin II receptor blockers (ARB) and statin during the study period were obtained from the patients' medical records.
Assessment of ABI and brachial-ankle pulse wave velocity
Ankle-brachial index and brachial-ankle pulse wave velocity (baPWV) were measured 10-30 min before a haemodialysis session using an ABI-form device which concurrently measured blood pressure (BP) in the patient's arms and ankles using an oscillometric method. 4, 5, 9, 10 ABI was calculated as the lowest value of systolic BP (SBP) in the ankle/SBP in the arm. For baPWV, pulse waves were concurrently recorded in brachial and tibial arteries, and the transmission time was calculated as the duration from the initial increase in brachial to tibial waveforms. The transmission distance was calculated as the distance from the arm to each ankle of the patient, and baPWV was calculated as the transmission distance/transmission time. The highest of bilateral baPWV values was used for each patient. ABI and baPWV values were measured concurrently in each patient.
Statistical analysis
All statistical analyses were performed using SPSS version 17.0 for Windows (SPSS Inc., Chicago, IL, USA). Data were expressed as percentage, mean AE standard deviation, or median (25th-75th percentile) for the duration of dialysis, and levels of triglycerides, intact parathyroid hormone (iPTH) and CRP. Comparisons among the study groups were conducted using one-way analysis of variance followed by a Bonferroni-adjusted post hoc test. Multiple logistic regression analysis was used to identify the factors associated with an ABI less than 0.9, and associations between the study groups and an ABI less than 0.9 were assessed using a modified stepwise procedure in a two-step model. The first model contained age, sex, diabetes mellitus (DM), hypertension, coronary artery disease, cerebrovascular disease, SBP and diastolic BP. The second model included biomarkers and medications including fasting glucose, log-transformed triglycerides, total cholesterol, highdensity lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, haemoglobin, creatinine, total calcium, phosphorous, calcium-phosphorous product, uric acid, iPTH, Kt/V, ACEI, ARB, β-blockers, calcium channel blockers and statins. The patients with a higher albumin level and lower CRP level were treated as the reference group at the lowest risk of ABI less than 0.9. Receiver operating characteristic (ROC) curves were constructed to predict an ABI less than 0.9. A difference was considered significant at P value less than 0.05.
RESULTS
Of the 222 haemodialysis patients, the mean age was 61.0 AE 11.7 years, 115 (51.8%) were men, and the prevalence of an ABI less than 0.9 was 25.2%. The study patients were stratified into four groups according to the median values of albumin (3.87 g/dL) and log-transformed CRP (0.48 mg/L). Comparisons of the clinical characteristics among the study groups are shown in Table 1 . The prevalence rates of an ABI less than 0.9 in the four groups were 8.6%, 20.8%, 27.8% and 43.9%, respectively (P for trend <0.001). The group with a lower albumin level and higher CRP level had the highest ABI among the four groups.
Relationships of the study groups to an ABI less than 0.9 *P < 0.05 compared with higher albumin and lower CRP. **P < 0.05 compared with higher albumin and CRP. ***P < 0.05 compared with lower albumin and CRP. †
The study patients were stratified into four groups according to median values of albumin (3.87 g/dL) and log CRP (0.48 mg/L). ABI, ankle-brachial index; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; baPWV, brachial-ankle pulse wave velocity; CRP, C-reactive protein; HDL, high-density lipoprotein; iPTH, intact parathyroid hormone; LDL, low-density lipoprotein.
significant after further adjustments for biomarkers including fasting glucose, log-transformed triglycerides, total cholesterol, HDL-cholesterol, LDL-cholesterol, haemoglobin, creatinine, total calcium, phosphorous, calciumphosphorous product, uric acid, iPTH, Kt/V and medications including ACEI, ARB, β-blockers, calcium channel blockers and statin (OR, 5.688; 95% CI, 1.369-23.626; P = 0.017).
The interaction between albumin and CRP (per g/dL × mg/L) in the patients with an ABI less than 0.9 was statistically significant in the unadjusted model (OR, 1.368; 95% CI, 1.141-1.639; P = 0.001) and multivariate model after adjustments for age, sex, co-morbidities, SBP and diastolic BP (OR, 1.371; 95% CI, 1.097-1.713; P = 0.006), and after further adjustments for biomarkers and medications (OR, 1.797; 95% CI, 1.258-2.568; P = 0.001).
Comparisons of albumin, CRP and albumin + CRP in the prediction of an ABI less than 0.9
The ROC curves for albumin, CRP and albumin + CRP in the prediction of an ABI less than 0.9 are shown in Figure 1 
DISCUSSION
In the present study, the haemodialysis patients with both a lower albumin and higher CRP levels were associated with an ABI less than 0.9. The interaction between a lower albumin level and higher CRP level was also associated with an ABI less than 0.9 after adjusting for covariates. Therefore, a combination of malnutrition and inflammation was a risk factor for the development of PAOD in haemodialysis patients.
Several risk factors for atherosclerosis have been reported in patients with ESRD, including aging, DM, a history of cardiovascular and cerebro-vascular disease, increased pulse pressure, a low level of serum albumin and a high level of CRP. 4, 7, 8, 12 Moreover, uraemia itself has been reported to facilitate the progression of PAOD through various mechanisms including vascular calcification, changes in inflammatory and coagulation pathways, oxidative stress, malnutrition and infection. [13] [14] [15] Our results indicated that a combination of lower albumin and higher CRP levels was associated with an ABI less than 0.9. This suggests that malnutrition and inflammation are both important risk factors for PAOD in patients with ESRD, and that haemodialysis patients with both a lower albumin and higher CRP levels are at an increased and synergetic risk of PAOD. Most previous studies have discussed the influence of inflammation or malnutrition on PAOD separately. In a cross-sectional study of an elderly Japanese population, patients with higher levels of CRP had lower ABI values. 16 In addition, Ridker et al. and Tzoulaki et al. reported that found an association between PAOD and serum albumin in patients with peritoneal dialysis, but not in those undergoing haemodialysis. 24, 25 The combination of a lower albumin and elevated CRP levels has also been associated with clinical outcomes after endovascular therapy in haemodialysis patients with PAOD. 26 In patients with ESRD, CRP is commonly used as a marker of inflammation status. ESRD itself may be regarded as a chronic systemic inflammatory state. 27 In turn, activation of the inflammatory system causes the synthesis of CRP and may inhibit the hepatic generation of albumin. 7, 12 A high CRP level may induce endothelial dysfunction and greater arterial wall inflammation, thereby promoting the invasion of inflammatory cells, thrombosis and plaque rupture. 28 Our results indicate that the combination of malnutrition and inflammation may increase the risk of PAOD in patients with ESRD. This finding is important for clinicians, and may allow for the early identification of PAOD in patients undergoing haemodialysis. Malnutrition-inflammation status correlates with the severity of endothelial dysfunction, one major pathogenetic factor for PAOD, as well as serum vascular cell adhesion molecule-1 (VCAM-1) and oxidized low-density lipoprotein cholesterol (oxLDL) levels, in haemodialysis patients. 29 Statin can attenuate VCAM-1 expression in endothelial cell and reduce oxLDL levels. 30, 31 Furthermore, a meta-analysis showed that statin decrease serum CRP levels significantly and can improve inflammatory status in dialysis patients. 32 Thus, statin might play a pivotal role of pharmaceutical therapy for complex of malnutrition-inflammation and PAOD in patients with ESRD. There are several limitations in this study. First, this was a cross-sectional study, which makes it difficult to identify causality. Second, this study was conducted in a single regional hospital, and therefore the selection of patients was limited and the sample size was relatively modest. Third, ABI measurements were performed only once in each patient, which may have caused bias. In addition, albumin and CRP are only indicators, utility of malnutritioninflammation score could be a more comprehensive assessment. Finally, we did not stop the use of medications in our patients due to ethical concerns. Hence, we adjusted for medication use in the multivariate analysis to minimize the influence of drugs.
In conclusion, the haemodialysis patients with a lower level of albumin and higher level of CRP were associated with an increased risk of PAOD. A combination of malnutrition and inflammation is an important risk factor of PAOD in haemodialysis patients. Our findings would remind physicians the importance of the effects of malnutrition and inflammation, and their interactions on ABI in patients with ESRD.
